IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
IDEXX LABORATORIES INC /DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$555.80−4.56 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $44.08B
- P/E (TTM)
- 39.1
- Dividend yield
- –
IDEXX LABORATORIES INC /DE revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAG segment revenue | $3.95B | $3.57B | $3.35B | $3.06B | $2.89B | $2.39B | $2.12B | – | – | – | 91.9% | +10.6% |
| Water segment revenue | $201.15M | $185.11M | $168.15M | $155.72M | $146.51M | $128.63M | $132.85M | $125.20M | $114.40M | $103.58M | 4.7% | +8.7% |
| LPD | $131.79M | $122.06M | $121.66M | $122.61M | $135.89M | $145.85M | $132.64M | – | – | – | 3.1% | +8.0% |
| Other segment revenue | – | – | $18.79M | $30.20M | $43.01M | $46.42M | $22.24M | $22.04M | $22.81M | $22.66M | – | – |
| LPD | – | – | – | – | – | – | $132.64M | $130.58M | $128.48M | $126.49M | – | – |
| CAG segment revenue | – | – | – | – | – | – | $2.12B | $1.94B | $1.70B | $1.52B | – | – |
| LPD | – | – | – | – | – | $145.85M | $132.64M | $130.58M | – | – | – | – |
| CAG segment revenue | – | – | – | – | – | $2.39B | $2.12B | $1.94B | – | – | – | – |
| CAG Diagnostics [Member] | – | – | – | – | – | – | – | – | – | $1.40M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CAG segment revenue | – | – | $1.01B | $800.95M | $824.02M | $574.89M | $462.61M | – | – | – | – |
| Water segment revenue | – | – | $74.34M | $72.52M | $65.44M | $58.87M | $61.92M | $56.64M | $50.62M | $45.70M | – |
| LPD | – | – | $9.98M | $19.81M | $28.64M | $40.01M | $24.74M | – | – | – | – |
| Other segment revenue | – | – | $73.00K | $5.49M | $13.93M | $20.76M | $3.58M | $2.62M | $4.84M | $884.00K | – |
| Unallocated Amounts | – | – | – | – | – | – | – | – | -$22.45M | -$16.60M | – |
| LPD | – | – | – | – | – | – | $25.37M | $19.41M | $16.46M | $18.91M | – |
| CAG segment revenue | – | – | – | – | – | – | $491.60M | $429.48M | $363.56M | $301.34M | – |
| LPD | – | – | – | – | – | $40.01M | $24.74M | $19.45M | – | – | – |
| CAG segment revenue | – | – | – | – | – | $574.89M | $462.61M | $412.62M | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $2.54B | $2.25B | $2.09B | $1.93B | $1.88B | $1.59B | $1.42B | $1.32B | $1.18B | $1.07B | 59.0% | +12.9% |
| Service revenue | $1.76B | $1.65B | $1.57B | $1.44B | $1.34B | $1.12B | $983.76M | $890.56M | $792.94M | $704.45M | 41.0% | +7.0% |
| Rapid Assay Products [Member] | – | – | – | – | – | – | – | – | $205.31M | $189.12M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $3.01B | $2.77B | $2.63B | $2.40B | $2.20B | $1.85B | $1.65B | $1.50B | $1.33B | $1.20B | 70.0% | +8.7% |
| United States | $2.75B | $2.53B | $2.39B | $2.18B | $2.00B | $1.69B | $1.50B | $1.36B | $1.20B | $1.09B | 64.0% | +8.7% |
| Europe, the Middle East and Africa | $937.25M | $806.73M | $716.18M | $647.03M | $681.95M | $562.77M | $498.44M | $472.07M | $419.42M | $375.76M | 21.8% | +16.2% |
| Asia Pacific | $355.93M | $321.02M | $319.31M | $319.55M | $331.38M | $293.41M | $256.89M | $238.09M | $215.38M | $196.27M | 8.3% | +10.9% |
| Other | $230.03M | $196.31M | $176.40M | $161.58M | $167.53M | $148.05M | $122.21M | $114.88M | $100.41M | $83.15M | 5.3% | +17.2% |
| Germany | $206.76M | $173.68M | $149.79M | $137.88M | $146.76M | $119.35M | $104.08M | $100.46M | $88.33M | $80.16M | 4.8% | +19.0% |
| Canada | $167.33M | $152.89M | $150.11M | $142.74M | $139.73M | $107.40M | $99.55M | $94.21M | $83.82M | $74.92M | 3.9% | +9.4% |
| United Kingdom | $154.44M | $134.63M | $121.75M | $110.40M | $114.96M | $90.16M | $90.97M | $87.81M | $80.15M | $77.67M | 3.6% | +14.7% |
| France | $126.00M | $110.80M | $96.80M | $84.48M | $90.84M | $74.81M | $64.77M | $60.32M | $55.99M | $51.20M | 2.9% | +13.7% |
| Other | $124.36M | $110.10M | $104.11M | $96.29M | – | – | – | – | – | – | 2.9% | +13.0% |
| Australia | $112.25M | $101.96M | $95.47M | $96.41M | $94.41M | $79.63M | $71.07M | $63.39M | $56.99M | $52.87M | 2.6% | +10.1% |
| Latin America & Caribbean | $90.41M | $83.69M | $83.92M | $75.04M | $66.62M | $51.86M | $56.52M | – | – | – | 2.1% | +8.0% |
| Japan | $83.36M | $73.14M | $75.57M | $77.66M | $84.28M | $74.73M | $67.25M | $60.21M | $53.34M | $51.54M | 1.9% | +14.0% |
| Spain | $70.97M | $61.86M | $52.33M | $46.98M | $48.17M | $39.27M | $36.44M | $33.69M | $28.87M | $24.27M | 1.6% | +14.7% |
| Italy | $66.86M | $58.22M | $53.79M | $48.19M | $52.06M | $42.82M | $39.73M | $36.96M | $31.89M | $28.91M | 1.6% | +14.8% |
| Switzerland | $41.70M | $37.18M | $34.83M | $30.65M | $31.98M | $24.85M | $20.86M | $19.88M | $17.91M | $16.36M | 1.0% | +12.1% |
| Netherlands | $40.50M | $34.05M | $30.51M | $26.88M | $29.66M | $23.46M | $19.40M | $18.09M | $15.88M | $14.05M | 0.9% | +19.0% |
| China | $35.96M | $35.82M | $44.17M | $49.19M | $63.17M | $70.85M | $57.52M | $57.62M | $55.81M | $48.26M | 0.8% | +0.4% |
| Latin America | – | – | – | – | – | $51.86M | $56.52M | $50.97M | $46.89M | $38.87M | – | – |
| Other | – | – | $104.11M | $96.29M | $89.52M | $68.21M | $61.06M | $56.87M | $49.23M | $43.60M | – | – |
From the segment and revenue-disaggregation notes of Idexx Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.